MNOV (Medicinova Inc) stock: $1.46, $71.9M market cap, $25.4M cash, $46.5M EV, $84.0M fully diluted market cap. Next expected readout: Dec-26. Lead program: MN-166 (Amyotrophic Lateral Sclerosis), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Mayo Foundation for Medical Education and Research (clinical research services agreement to evaluate MN-166 in ALS)
Indications
Progressive multiple sclerosis (MS)(Stage not disclosed)
Amyotrophic lateral sclerosis (ALS)(Stage not disclosed)
Chemotherapy-induced peripheral neuropathy(Stage not disclosed)
Degenerative cervical myelopathy (DCM)(Stage not disclosed)
Glioblastoma(Stage not disclosed)
Prevention of acute respiratory distress syndrome (ARDS)(Stage not disclosed)
Status note Advanced through investigator-sponsored, government/grant-funded, and company-funded trials. Mayo Foundation clinical research services agreement (December 2024, extended to August 2026) to evaluate MN-166 in ALS; first study site enrolled patients in March 2025.
MN-001
Stage not disclosed · Active
Aliases tipelukast
Target LT receptor / PDE3/4 / 5-LO
Indications
Fibrotic disorders (e.g., nonalcoholic fatty liver disease/NAFLD)(Stage not disclosed)
Metabolic disorders (e.g., hypertriglyceridemia)(Stage not disclosed)
Status note Second named product candidate; company intends to advance development through investigator-sponsored or grant-funded trials as well as company-funded trials.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.